Differential Expression Of Peripheral Serum Protein In Patients With Metastatic And Non-Metastatic Melanoma By MALDI-TOF-MS

Background and ObjectiveTo analyze the differential expression of peripheral serum protein in patients with metastatic and non-metastatic melanoma by proteomic technology, and explore the clinical significance for the diagnosis of patients with metastatic melanoma.Methods101cases were selected, and the patients were divided into the group of patients with metastatic melanoma (n=25) and control groups (31eases with non-metastatic melanoma,45cases healthy people.73cases (18cases with metastatic melanoma,20cases with non-metastatic melanoma and35cases healthy people) were randomly selected as diagnostic model group, the rest of the23cases (7cases with metastatic melanoma,11cases with non-metastatic melanoma and10cases healthy people) were used to verify the diagnosis model by blind means. MALDI-TOF-MS was applied to detect the peripheral serum protein. Ciphergen protein chips were used to analyze the protein profiling. ResultsCompared the peripheral serum proteins of patients with those of the control groups, the mass-to-charge ratio were1528.33,2046.79,3685.48,4392.10,5756.64and11670.82m/z. The different expression of six protein peaks was statistically significant (The average P value is0.000respectively). Diagnostic model of metastatic melanoma was built according to it. The sensitivity of diagnostic model group was83.33%, and the specificity was74.55%. In addition, the test groups were used to verify this model by blind means. The sensitivity of metastatic melanoma was71.43%, and the specificity was74.55%ConclusionCompared the expression of peripheral serum protein in patients with metastatic melanoma with the control groups,(they) have the statistic significant. The relative molecular mass (1528.33,2046.79,3685.48,4392.10,5756.64and11670.82m/z) of protein can be used as biological markers in the diagnosis of early metastatic melanoma.